Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Categories: @cannabis-players   

CV Sciences, Inc. provides specialty pharmaceutical products. The Company focuses on manufacturing, marketing, and selling plant-based CBD products to a range of market sectors, as well as develops CBD-based novel therapeutics utilizing CBD. CV Sciences invests in the scientific evidence necessary to receive self affirmed generally recognized as safe (GRAS) status.
  • Current market environment: positive. Prices of production are 12.2% higher compared to the last 12 months (LTM)
  • Prices of production are at 52.4% percentile over the past 5 years, adjusted for inflation
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 0.0% (LTM), projected 13.0%
  • Share price is 59.8% higher than minimum and 62.1% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (-3.3x vs
    )
  • The company is undervalued by EV / projected EBITDA multiple compared to target level (
    vs
    )

Key Financials (Download financials)

Ticker: CVSI
Share price, USD:  (0.0%)0.03675
year average price 0.0398  


year start price 0.0680 2024-07-07

max close price 0.0680 2024-07-07

min close price 0.0230 2025-05-28

current price 0.0368 2025-07-06
Common stocks: 152 599 000

Dividend Yield:  0.0%
EV / LTM EBITDA: -3.3x
Production prices change from LTM: 12.2%
EV / projected EBITDA:
Target EV / EBITDA (hist percentile):
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 6
Net Debt ($m): 1
EV (Enterprise Value): 7
EBITDA LTM ($m): -2
EV / LTM EBITDA: -3.3x
Price to Book: 3.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / LTM EBITDA and 75% percentile

Potential dynamics

News


2025-06-23accessnewswire.com

CV Sciences, Inc. Applauds Governor Abbot's Veto of Senate Bill 3

2025-05-14seekingalpha.com

CV Sciences, Inc. (CVSI) Q1 2025 Earnings Call Transcript

2025-05-09accessnewswire.com

CV Sciences, Inc. to Announce First Quarter 2025 Results on May 14, 2025

2025-03-27seekingalpha.com

CV Sciences, Inc. (CVSI) Q4 2024 Earnings Call Transcript

2025-03-20accessnewswire.com

CV Sciences, Inc. To Announce Year End and Fourth Quarter 2024 Results On March 27, 2025

2024-11-21prnewswire.com

CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs

2024-08-27prnewswire.com

CV Sciences Launches +PlusHLTH, a New Line of Cannabinoid-Free Supplements

2024-08-13seekingalpha.com

CV Sciences, Inc. (CVSI) Q2 2024 Earnings Call Transcript

2023-11-14Seeking Alpha

CV Sciences, Inc. (CVSI) Q3 2023 Earnings Call Transcript

2023-08-14Seeking Alpha

CV Sciences, Inc. (CVSI) Q2 2023 Earnings Call Transcript
More information for subscribed users:
detailed calculation of Potential,
commodities and currency affecting the company